Abcam & Cancer Research UK join forces to accelerate cancer research
By Akshay Kedari  Date: 2020-07-09

Abcam & Cancer Research UK join forces to accelerate cancer research

Cancer Research UK, one of the world's biggest independent funder of cancer research, has recently joined forces with Abcam plc, a leading developer of life science tools and reagents, to commercialize and develop novel custom antibodies to strengthen cancer research.

According to the terms of this partnership, Abcam would create custom protein-based reagents to targets that are recognized by researchers at Cancer Research UK. These antibodies would support the ongoing research and progress the understanding of cancer biology. Moreover, it would potentially be the basis for novel therapies as well as help generate new diagnostic tools.

Upon request, Abcam would deliver unique antibodies created during the terms of the agreement to researchers funded by Cancer Research UK for a pre-determined span of exclusivity in correspondence to that antibody. 

Meanwhile, Abcam’s co-location in key technology spots throughout the world and global supply capability would allow these innovative reagents to be easily available across wider diagnostic and research development community.

Speaking on the move, Tony Hickson, CBO, Cancer Research UK, said that the company is thrilled to collaborate with Abcam to develop tools that scientists require to help advance their understanding of cancer and to extend its access to biological reagents.

Additionally, Abcam’s “end-to-end” expertise and antibody development capabilities would support works of numerous researchers with antibody reagents that could be utilized from the initial stages of R&D right to the clinical trials.

As for Dr. John Baker, SVP of Product Portfolio Innovation, Abcam, the company is delighted to partner with Cancer Research UK to strengthen research by scientist and offer them easy access to validated and specific reagents, thereby helping them attain future breakthrough quickly.

Prior to this news, Abcam had made headlines when it announced that it has purchased assets of oncology product portfolio and gene editing platform from Applied StemCell, Inc. (ASC) for life science diagnostic and research markets. 
 

Source credit: https://www.abcam.com/index.html?pageconfig=news&rid=17091

About Author

Akshay Kedari    

Akshay Kedari

A qualified computer engineering graduate, Akshay Kedari takes pride in having his way with words. Following his passion for content creation, he writes insightful pieces on aeresearch.net and a few other portals. Also endorsed with a short-term experience in web deve...

Read More

More News By Akshay Kedari

RADCOM introduces automated assurance solution for 5G technology
RADCOM introduces automated assurance solution for 5G technology
By Akshay Kedari

5G technology has been in the headlines for quite a while. Next-generation technology has the potential to transform almost every sector across the world. However, as 5G becomes reality, it has become imperative for service providers to prevent degra...

Sprout to expand wellness solutions lineup by acquiring Vivametrica
Sprout to expand wellness solutions lineup by acquiring Vivametrica
By Akshay Kedari

Sprout, a Canadian company that focuses on delivering innovative solutions for workplace wellbeing, has recently announced the acquisition of predictive health data analytics firm, Vivametrica. According to reliable sources, Sprout plans to enhance t...

Uber halts decision to shift APAC headquarters from Singapore
Uber halts decision to shift APAC headquarters from Singapore
By Akshay Kedari

Uber Technologies Inc., the American ride-hailing giant, has reportedly halted the company’s decision to relocate its Asia Pacific headquarters from Singapore to Hong Kong until December 2022. Sources cite that the company’s decision was...

PCI Pharma extends global clinical supply-chain services in Europe
PCI Pharma extends global clinical supply-chain services in Europe
By Akshay Kedari

U.S. based biopharmaceutical and pharma outsourcing services company, PCI Pharma services has reportedly announced that it reached a noteworthy milestone through the development of COE (Clinical Center of Excellence) in Berlin. According to credible...

Dassault to use Proxem’s AI solution to advance 3DEXPERIENCE platform
Dassault to use Proxem’s AI solution to advance 3DEXPERIENCE platform
By Akshay Kedari

French software company, Dassault Systèmes has recently revealed plans to enhance its 3DEXPERIENCE platform’s collaborative data science abilities, allowing customers to take advantage of their data patrimony by taking part in new v...